SCHEMBL5606071

SCHEMBL5606071

CC(=O)C(c1ccccc1)[C@H](N)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.56
KMT2A Q03164 2/20 0.47
SRC P12931 1/20 0.45
DPP4 P27487 2/20 0.44
LMNA P02545 2/20 0.43
MAPK1 P28482 1/20 0.43
SLC1A3 P43003 3/20 0.43
SLC1A2 P43004 3/20 0.43
SLC1A1 P43005 3/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALOX5 P09917 1/20 0.43
ALPI P09923 1/20 0.42
PKM P14618 1/20 0.42
PTGS1 P23219 1/20 0.42
XIAP P98170 1/20 0.42
SLC7A5 Q01650 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576405 1.00 CYP2D6 (0.56) CYP2D6KMT2ASRCDPP4LMNA
SCHEMBL3630110 1.00 CYP2D6 (0.56) CYP2D6KMT2ASRCDPP4LMNA
SCHEMBL3582437 1.00 CYP2D6 (0.56) CYP2D6KMT2ASRCDPP4LMNA
SCHEMBL2308229 0.85 CYP2D6 (0.70) CYP2D6KMT2ASRCDPP4LMNA
SCHEMBL7519804 0.85 CYP2D6 (0.70) CYP2D6KMT2ASRCDPP4LMNA
SCHEMBL28455786 0.85 SLC7A5 (0.46) CYP2D6KMT2ASRCLMNASLC1A3
SCHEMBL5785054 0.85 SLC7A5 (0.46) CYP2D6KMT2ASRCLMNASLC1A3
Hydrochloric Acid SCHEMBL5693429 0.83 CYP2D6 (0.67) CYP2D6KMT2ASRCDPP4LMNA
Morpholine SCHEMBL7297008 0.83 CYP2D6 (0.40) CYP2D6KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL16728482 0.83 UGT2B7 (0.47) CYP2D6KMT2ASLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243472-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-07-31 US claimed
US-20230212535-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-07-06 US claimed
EP-4198125-A2 PIF1-LIKE HELICASE AND USE THEREOF Qitan Technology Ltd., Beijing (CN) 2023-06-21 EP claimed
US-11525125-B2 Modified helicases OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2022-12-13 US claimed
EP-4063382-A9 PIF1-LIKE HELICASE AND APPLICATION THEREOF Qitan Technology Ltd., Beijing (CN) 2022-11-16 EP claimed
EP-4063382-A1 PIF1-LIKE HELICASE AND APPLICATION THEREOF Qitan Technology Ltd., Beijing (CN) 2022-09-28 EP claimed
US-20220290223-A1 PIF1-LIKE HELICASE AND USE THEREOF Qitan Technology Ltd. (CN) 2022-09-15 US claimed
US-20210009971-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2021-01-14 US claimed
EP-3575410-A2 MODIFIED ENZYMES Oxford Nanopore Technologies Limited (GB) 2019-12-04 EP claimed
US-20180037874-A9 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2018-02-08 US claimed
US-20160257942-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2016-09-08 US claimed
EP-3058088-A2 MODIFIED ENZYMES Oxford Nanopore Technologies Limited (GB) 2016-08-24 EP claimed
US-20150191709-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2015-07-09 US claimed
EP-2875128-A1 MODIFIED HELICASES Oxford Nanopore Technologies Limited (GB) 2015-05-27 EP claimed
WO-2015055981-A2 MODIFIED ENZYMES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2015-04-23 WO claimed
WO-2014013260-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2014-01-23 WO claimed
US-20260028379-A1 MUTANT PORE OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-01-29 US disclosed
US-20250243472-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-07-31 US disclosed
WO-2014013260-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2014-01-23 WO disclosed
WO-2007085887-A1 PYY AGONISTS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028379-A1 MUTANT PORE PTMS, NUP50, NUP205 CYP2D6 2833/4885KMT2A 2059/4885SRC 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.